Search results for " Inflammatory Bowel Disease"

showing 10 items of 65 documents

Indicaxanthin inhibits NADPH oxidase (NOX)-1 activation and NF-κB-dependent release of inflammatory mediators and prevents the increase of epithelial…

2014

Dietary redox-active/antioxidant phytochemicals may help control or mitigate the inflammatory response in chronic inflammatory bowel disease (IBD). In the present study, the anti-inflammatory activity of indicaxanthin (Ind), a pigment from the edible fruit of cactus pear (Opuntia ficus-indica, L.), was shown in an IBD model consisting of a human intestinal epithelial cell line (Caco-2 cells) stimulated by IL-1β, a cytokine known to play a major role in the initiation and amplification of inflammatory activity in IBD. The exposure of Caco-2 cells to IL-1β brought about the activation of NADPH oxidase (NOX-1) and the generation of reactive oxygen species (ROS) to activate intracellular signal…

Cell Membrane PermeabilityPyridinesPyridinemedicine.medical_treatmentInterleukin-1betaMedicine (miscellaneous)Nitric Oxide Synthase Type IIIndicaxanthinNADPH OxidaseInflammatory bowel diseaseIntestinal absorptionAntioxidantschemistry.chemical_compoundSettore BIO/10 - BiochimicaInflammation MediatorCaco-2 CellNutrition and DieteticsNADPH oxidasebiologyNF-kappa BNADPH Oxidase 1OpuntiaCell biologyBetaxanthinsCytokineNADPH Oxidase 1EnterocyteAntioxidantmedicine.symptomInflammation MediatorsReactive Oxygen SpecieIndicaxanthinHumanRedox-active phytochemicalInflammationIn vitro modelmedicineHumansIndicaxanthin Betalain pigments Inflammatory bowel disease Redox-active phytochemicalsInterleukin 8Inflammationbusiness.industryInterleukin-6Interleukin-8NADPH OxidasesInflammatory Bowel DiseasesEnzyme ActivationEnterocyteschemistryIntestinal AbsorptionCaco-2Cyclooxygenase 2BetaxanthinFruitImmunologybiology.proteinCaco-2 CellsbusinessReactive Oxygen SpeciesThe British journal of nutrition
researchProduct

BONE LOSS I INFLAMMATORI BOWEL DISEASE: OUR MULTICENTRIC STUDY

2011

Patients with inflammatory bowel disease are at increased risk of developing disorder in bone and mineral metabolism. The study was aimed to determine if inflammatory bowel disease (IBD) is a risk factor for osteoporosis in 103 adult patients. We included 103 IBD patients, 67 patients with Crohn's disease (CD) and 36 with ulcerative colitisi (UC). Bone mineral density was measured by dual-energy X-ray absorptiometry. we used T score to express bone loss (osteopenia: -25SD 2 years) and active disease would be risk of bone mineral loss in IBD.

Settore MED/18 - Chirurgia GeneraleCrohn's disease Osteoporosis dexa inflammatory bowel disease ulcerative colitis.
researchProduct

Comment to “Management of cytomegalovirus infection in inflammatory bowel diseases”

2012

.

cytomegaloviruHepatologybusiness.industryGastroenterologyInflammatory Bowel DiseasesAntiviral AgentsInflammatory bowel diseaseCytomegalovirus infectionCrohn DiseaseCytomegalovirus InfectionsImmunologyHumansMedicineColitis Ulcerativecytomegalovirus; Inflammatory bowel diseasebusinessGanciclovircytomegalovirusImmunosuppressive AgentsDigestive and Liver Disease
researchProduct

A real life comparison of the efficacy of adalimumab versus golimumab in moderate-to-severe ulcerative colitis. A multicenter experience from the sic…

2017

Introduction: Adalimumab (ADA) and golimumab (GOL) are effective in the induction and maintenance treatment of moderate-to-severe ulcerative colitis (UC). No comparable data between the 2 drugs are available up to now. Aims & Methods: We reported the Sicilian Network experience on the comparative efficacy of ADA and GOL in patients (pts) with moderate-to-severe UC. From June 2015 until April 2017, 197 consecutive pts with moderate to severe UC were treated with ADA or GOL. The efficacy was evaluated at 8 week and at the end of the follow up considering ‘‘clinical response’’ (reduction of at least 2 points of Partial Mayo Score with concomitant steroid reduction or discontinuation) and “…

adalimumab; golimumab; ulcerative colitis; sicilian network; inflammatory bowel disease; SN-IBDsicilian networkSettore MED/09 - Medicina Internainflammatory bowel diseaseadalimumabSN-IBDgolimumabulcerative coliti
researchProduct

Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein–Coupled Receptor OGR1 (GPR68)

2016

Background & Aims: A novel family of proton-sensing G-proteinâcoupled receptors, including ovarian cancer G-proteinâcoupled receptor 1 (OGR1) (GPR68) has been identified to play a role in pH homeostasis. Hypoxia is known to change tissue pH as a result of anaerobic glucose metabolism through the stabilization of hypoxia-inducible factor-1α. We investigated how hypoxia regulates the expression of OGR1 in the intestinal mucosa and associated cells. Methods: OGR1 expression in murine tumors, human colonic tissue, and myeloid cells was determined by quantitative reverse-transcription polymerase chain reaction. The influence of hypoxia on OGR1 expression was studied in monocytes/macrophages and…

WT wild type0301 basic medicineMM6 MonoMac 6HV healthy volunteerSPARC secreted protein acidic and rich in cysteineNF-κB nuclear factor-κBInflammationBiologyIEC intestinal epithelial cell03 medical and health sciencesIntestinal mucosaTDAG8Ovarian Cancer G-Protein–Coupled ReceptormedicineOGR1 ovarian cancer G-protein–coupled receptor 1 (GPR68)IFN interferonlcsh:RC799-869ReceptorOriginal ResearchTh T-helperInflammationTNF tumor necrosis factorIBD inflammatory bowel diseaseHepatologyRT-qPCR quantitative reverse-transcription polymerase chain reactionAICAR 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranosideTDAG8 T-cell death-associated gene 8 (GPR65)Inflammatory Bowel DiseaseGRP65GastroenterologyHypoxia (medical)Molecular biologyGPR G-protein–coupled receptormRNA messenger RNAIL interleukinChIP chromatin immunoprecipitationHIF hypoxia-inducible factorUC ulcerative colitis030104 developmental biologyHypoxia-inducible factorsCancer researchCD Crohn's diseaselcsh:Diseases of the digestive system. GastroenterologyTumor necrosis factor alphaFCS fetal calf serummedicine.symptomChromatin immunoprecipitationHomeostasisCellular and Molecular Gastroenterology and Hepatology
researchProduct

Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of …

2017

Abstract The two main forms of intestinal bowel disease, namely ulcerative colitis and Crohn’s disease, are not curable but can be controlled by various medical therapies. The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) has prepared clinical practice guidelines to help physicians prescribe corticosteroids and immunosuppressive drugs for these patients. The guidelines consider therapies that induce remission in patients with active disease as well as treatment regimens that maintain remission. These guidelines complement already existing guidelines from IG-IBD on the use of biological drugs in patients with inflammatory bowel diseases.

medicine.medical_specialtyIBDDiseaseGuidelineGuidelinesInflammatory bowel diseaseGastroenterologyBiological drugs03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineMedicalmedicineCorticosteroidCorticosteroidsHumansIn patient030212 general & internal medicineCorticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Hepatology; GastroenterologySocieties MedicalCrohn's diseaseSettore MED/12 - GastroenterologiaUlcerative colitiHepatologybusiness.industryImmunosuppressorsRemission InductionGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisdigestive system diseasesClinical PracticeCrohn's diseaseUlcerative colitisItalyImmunosuppressorCorticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Adrenal Cortex Hormones; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Italy; Remission Induction; Societies Medical030211 gastroenterology & hepatologybusinessSocietiesImmunosuppressive Agents
researchProduct

Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study

2014

Remarkable differences in quality of care (QoC) might be observed in different countries, affecting quality of life of inflammatory bowel disease (IBD) patients. The aim of this study was to assess patient and physician perceptions of the QoC in Italy.A multicentre observational study on the quality of care in IBD (SOLUTION-1) was conducted in 36 IG-IBD (Italian Group for Inflammatory Bowel Disease) centres in Italy. The QUOTE-IBD (Quality of Care Through the Patient's Eyes) questionnaire was administered to IBD patients and to the attending physicians. The Quality Impact (QI) score summarises the QUOTE-IBD questionnaire, and a QI9 is considered satisfactory.Nine-hundred-ninety-two patients…

AdultMalemedicine.medical_specialtyquality impact score; quote-ibd; quality of careAdolescentAttitude of Health PersonnelQuality impact score; Quality of care; QUOTE-IBD; Adolescent; Adult; Aged; Aged 80 and over; Attitude of Health Personnel; Clinical Competence; Continuity of Patient Care; Female; Humans; Inflammatory Bowel Diseases; Italy; Male; Middle Aged; Patient Education as Topic; Patient Satisfaction; Professional Autonomy; Prospective Studies; Surveys and Questionnaires; Young Adult; Quality of Health Care; Medicine (all)Quality impact scoreGastroenterologyInflammatory bowel diseaseYoung AdultQUOTE-IBDPatient Education as TopicSurveys and QuestionnairesInternal medicineHealth care80 and overPhysician perceptionHumansMedicineProfessional AutonomyPharmaceutical SolutionsProspective StudiesQuality of careCompetence (human resources)AgedQuality of Health CareAged 80 and overbusiness.industryMedicine (all)Quality of careGastroenterologyQuality impact score; Quality of care; QUOTE-IBD; GastroenterologyGeneral MedicineContinuity of Patient CareMiddle AgedInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesItalyPatient SatisfactionFamily medicineFemaleContinuity of careObservational studyClinical CompetencebusinessJournal of Crohn's and Colitis
researchProduct

IBD, malignancy and oral microbiota: Analysis of the literature

2016

The human microbiota, in adults, varies in number and species based on the location in the gastrointestinal tract. The highest concentration is at the intestinal level, where mainly Bacteroidetes, Actinobacteria, Firmicutes and proteobacteria are found. Instead, in the oral cavity, five major phyla exists. Firmicutes, Actinobacteria, Proteobacteria, Bacteroidetes and Fusobacteria. Variations in the microbiota cause bysbiosis, which is responsible to a great extent for the onset of many diseases including inflammatory bowel disease (IBD) and colorectal cancer (CRC). In some cases (8-10%) IBD has shown oral manifestations that may reflect a change in the composition of the oral microbiota. Th…

dysbiosis gut microbiota Inflammatory Bowel Diseases colorectal cancer CRC IBDSettore MED/12 - GastroenterologiaSettore MED/06 - Oncologia Medica
researchProduct

Subclinical gut inflammation in ankylosing spondylitis

2015

Purpose of review Subclinical gut inflammation has been described in a significant proportion of patients with ankylosing spondylitis (AS), up to 10% of them developing it during the time of clinically overt inflammatory bowel disease. Histologic, immunologic, and intestinal microbiota alterations characterize the AS gut. Recent findings Microbial dysbiosis as well as alterations of innate immune responses have been demonstrated in the gut of AS. Furthermore, a growing body of evidence suggests that the gut of AS patients may be actively involved in the pathogenesis of AS through the production of proinflammatory cytokines, such as IL-23p19, and the differentiation of potentially pathogenic…

0301 basic medicineAnkylosing spondylitis; Gut inflammation; Innate lymphoid cells; Interleukin-17; Interleukin-23; Adaptive Immunity; Animals; Cytokines; Disease Models Animal; Dysbiosis; Gastrointestinal Microbiome; Humans; Immunity Innate; Inflammation; Inflammatory Bowel Diseases; Intestines; Macrophages; Mice; Spondylitis Ankylosing; Rheumatology; Medicine (all)MacrophageAdaptive ImmunityInterleukin-23Inflammatory bowel diseaseGastroenterologyMiceInterleukin 23InnateMedicineSubclinical infectionMedicine (all)Interleukin-17digestive oral and skin physiologyInnate lymphoid cellIntestineIntestinesCytokinesmedicine.symptomHumanAnkylosingmedicine.medical_specialtyDisease ModelInflammationdigestive system03 medical and health sciencesRheumatologyInternal medicineInnate lymphoid cellAnimalsHumansSpondylitis AnkylosingCytokineSpondylitisGut inflammationSpondylitiInflammationAnkylosing spondylitisAnimalbusiness.industryMacrophagesInflammatory Bowel DiseaseImmunityInflammatory Bowel Diseasesmedicine.diseaseImmunity InnateDysbiosiGastrointestinal MicrobiomeAnkylosing spondylitiDisease Models Animal030104 developmental biologyDysbiosisbusinessDysbiosisCurrent Opinion in Rheumatology
researchProduct

Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.

2020

This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions

MaleTime FactorsDiseaseInflammatory bowel diseaseInflammatory bowel diseasesurgeryAnti-TNFBiological Factors0302 clinical medicineAnti-TNF Immunosuppressants Inflammatory bowel disease SurgeryCrohn DiseaseimmunosuppressantsRisk Factorsanti‐TNFGastroenterologyAge FactorsMiddle AgedUlcerative colitisNatural history030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleImmunosuppressive AgentsCohort studyAdultmedicine.medical_specialtyMedicinaDisease-Free Survival03 medical and health sciencesEarly surgeryYoung AdultGastrointestinal Agentsinflammatory bowel diseaseInternal medicinemedicineHumansSurvival analysisRetrospective StudiesHepatologybusiness.industryTumor Necrosis Factor-alphamedicine.diseasedigestive system diseasesInfliximabImmunosuppressantsSurgeryColitis Ulcerativebusiness
researchProduct